Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nintedanib + mFOLFOX6
- Development stage
- Phase 2
- Lead developer
- Boehringer Ingelheim
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Nintedanib + mFOLFOX6 is a combination therapy consisting of **nintedanib**, a small molecule triple angiokinase inhibitor, and the **mFOLFOX6 chemotherapy regimen**, which includes oxaliplatin, folinic acid (leucovorin), and fluorouracil (5-FU)[1][3][5]. Nintedanib targets angiogenesis by inhibiting vascular endothelial growth factor receptors (VEGFR 1-3), fibroblast growth factor receptors (FGFR 1-3), and platelet-derived growth factor receptors (PDGFR α and β), thereby interfering with tumor blood vessel formation[3][5]. mFOLFOX6 is a widely used chemotherapy regimen that combines oxaliplatin, folinic acid, and fluorouracil for the treatment of colorectal cancer[2][4]. The combination has been investigated primarily for metastatic colorectal cancer (mCRC).
- Brand names
- Vargatef
- Other names
- nintedanib plus mFOLFOX6nintedanib + modified FOLFOX6
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FLT3 (Fms related receptor tyrosine kinase 3)LCK (Proto-oncogene tyrosine-protein kinase Lck)LYN (LYN proto-oncogene, Src family tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)SRC (Proto-oncogene tyrosine-protein kinase Src)TS (Thymidylate synthase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nintedanib + mFOLFOX6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nintedanib + mFOLFOX6.